

Not for distribution to United States newswire services or for dissemination in the United States.

The Canadian National Stock Exchange has not approved nor disapproved the contents of this press release.

MERUS LABS INTERNATIONAL INC.

ANNOUNCES NON-BROKERED PRIVATE PLACEMENT AND LISTING ON BERLIN STOCK EXCHANGE

VANCOUVER, November 16, 2010

CNSX Symbol: MR

Merus Labs International Inc. (“Merus”) is pleased to announce the closing on November 15, 2010 of the first tranche of its previously announced private placement. Merus sold 952,000 units at a price of \$0.25 per unit (the “Units”) for aggregate proceeds of CAD\$238,000 (the “Private Placement”). Each Unit offered in the Private Placement is comprised of one common share and one common share purchase warrant (the “Warrant”). Each Warrant is exercisable for 18 months at an exercise price of \$0.40 per share.

A commission of 8% of the proceeds paid from certain subscribers has been paid in cash to finders. In addition a commission of 8% of the units sold to certain subscribers was paid to finders in the form of commission warrants which are exercisable for 18 months with an exercise price of \$0.40 per share.

Merus intends to use the proceeds raised from the issuance of these securities for its general working capital.

Merus is also pleased to announce that it has obtained secondary listing on the Berlin Stock Exchange. Trading will commence on or about November 19, 2010 under the symbol MLA.BE.

Ahmad Doroudian, President, CEO and Director said, “The listing in Germany is an important event as our company will benefit from increased exposure to the European capital markets. By listing on the Berlin Exchange we now offer European investors the opportunity to invest in and to trade Merus' shares alongside our market on the Canadian National Stock Exchange.”

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in acquisition and licensing of pharmaceutical products. The company utilizes its expertise in the North American pharmaceutical markets and its access to capital to acquire and license niche branded products in Canada and United States. Merus further enhances the sale and distribution of these products by introduction of a focused marketing and promotion plan.

For further information please contact:

Dr. Ahmad Doroudian
Chief Executive Officer
Merus Labs International Inc.
Tel: (604) 805-7783
adoroudian@meruslabs.com